After US Surgeon General Jerome M. Adams, MD, MPH, urged more Americans to carry naloxone to reverse opioid overdoses, organizations and medical experts praised the decision.
A new deal between pharma giants AbbVie and Samsung Bioepis is designed to postpone competition against a biosimilar to Humira until 2023.
FDA okayed the marketing of a new continuous glucose monitoring system for diabetics—the first to be used as part of an integrated system with other compatible medical devices and electronic interfaces.
FDA’s approval of a new combination treatment for patients with classical Hodgkin lymphoma (cHL) is the first new advanced treatment for the disease in 40 years
Due to problems with compounded medications— including the 2012 fungal meningitis outbreak that led to 64 deaths—FDA is releasing a draft guidance that will determine which bulk drug substances outsourcing facilities can use to compound drugs.
President Donald Trump was expected to announce a new plan to combat the opioid crisis, even as a recent study found that prescription opioids were not as effective as over-the-counter medications for pain management.
As FDA considers new guidelines on pharmaceutical product marketing, a new study found that pharma makers may not be following current FDA ad regulations.
Over the past few months, several new diabetes treatments have been approved by FDA. Here are the top 3 novel drugs for diabetes.
A new FDA-approved drug offers new hope for patients with multidrug-resistant HIV-1 infection.
FDA approved the first direct-to-consumer test for three specific BRCA1/BRCA2 breast cancer gene mutations.